Building Wealth For Those Who Follow!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CUR treatment for ALS has really hit close to home. I found out yesterday that my sister in law was just diagnosed with ALS but has had symptoms for about a year.
I pray for a real treatment for all those that are suffering from this cruel disease.
You're a great man Sheff and that was wonderful. My son has type 1 diabetes and has been a huge struggle but it's something that can be managed. Cancer is just brutal and it took my dad 5 years ago.
Keep up the great work!
YIKES!!! I wonder how many people said that's okay as long has you're sorry. I'll try it on my wife and see how she takes it .
I like ATHX. Took a position also.
I don't believe that OTC is approved for Sheff's board.
Thanks
Been following and buying sense 6$. Frost is amazing. Think OPK was his last project :(
UGHH. I averaged down twice thinking you were still in.
Hoping for a great conference from them on the 9th now.
TGTX - TG-1101, we now are approaching 100% response rates in chronic lymphocytic leukemia patients." TG Therapeutics will start a Phase 3 study with ibrutinib later in 2015, and is looking at additional combinations. To give a sense of the potential, Pantginis shared the story of a patient who'd failed four previous Rituxan regimens and was about to be admitted to hospice. When put on TG-1101, she "converted to a complete response and hasn't looked back yet. And that was as a monotherapy. So very, very promising."
TG Therapeutics' second product, TGR-1202, is a PI3K kinase inhibitor, "again, a very hot target," Pantginis said. The drug candidate is showing "very good response rates in lymphoma patients. What's interesting is that this is a once-per-day drug, compared to twice-a-day with other drugs and, importantly, has not shown any of the liver toxicities seen with other PI3K inhibitors." He also noted that TG, with a $689M market cap, was a top-performing stock last year in biotech and is the Focus Pick of his firm. "We think the stock has room to grow here. . .these hot targets are literally just scratching the surface from TG."
Cabos, I've been trading for a long time and I'm still learning. The last time you posted saying you were done because of the 300k you lost made me take a step back and reevaluate my strategy and wonder what I would have done in your shoes.
Why on earth would anyone trade their retirement funds or money that you couldn't afford to loose in a market that anything could and will happen that could result in a total loss of capital?
I truly feel bad for those that take a hit has hard as you but question why I guess.
Best of luck to you and hope you recover every penny you have lost.
APPY getting beat down premarket. Great timing on your trade for those who got out.
Sweet trade again musthavemusic! ! Way to go :)
KYTH- LOL !!
MEIP- Anyone watch how this has been trading the past 2 weeks that can comment ? Totally looks like it's being manipulated some how to me.
Took a strong position in MEIP! Great seeking alpha article out on it today.
Nice trade musthavemusic!
Sheff only allows certain otc stocks on his board and don't believe this is one of them. Thanks
EDAP NICE FREAKING CALL BOB!! WOWZA
MEIP Nice looking chart. I'll do some digging. Thanks
I've seen some of Zacks rankings compared to other ranking and I've been truly confused on how they even came up with what they said. I don't put a lot of faith in them. That's just me tho.
Have a safe holiday Sheff Station!
VSTM trying to break 9$ from my 8.40 alert on the 27th. 21$ targets with many insider buying going on.
VSTM - Looking good here for 2015 imo!
Without a doubt, Verastem's biggest catalyst is a clinical trial called Command, testing VS-6063 in patients with mesothelioma, a form of lung cancer. The 350 to 400 patients expected to enroll in the trial have already responded to a combination of Eli Lilly's (NYSE: LLY ) Alimta and a platinum-based chemotherapy but haven't yet progressed following treatment.
Coming in as a closer -- if I can use a baseball analogy -- to finish off the remaining cells in the tumor is a smart move. Verastem doesn't have to compete directly with Eli Lilly and avoids the really hard-to-treat patients who might not respond to its treatment but doesn't have to wait for patients to progress like a typical second-line treatment.
While Command is only a phase 2 trial, it's designed to be sufficient to gain FDA approval given the unmet need in patients with mesothelioma.
Interim results for Command are expected in the middle of 2015. Management promised an update on the trial's enrollment at the research and development day, so perhaps that date could move up if enrollment is going well or maybe later if patients are responding better than expected. Investors should be careful interpreting a delay as good news, because interim data can also be delayed if the placebo group is living longer than the initial estimate or if enrollment is slower than expected.
Verastem is in a race with GlaxoSmithKline (NYSE: GSK ) , which also has a FAK inhibitor dubbed GSK2256098, so data that's quick and/or produces longer survival is welcome. GlaxoSmithKline's drug is still in phase 1 trials.
I bought CTSO in march at .23 cents! ! Sweet
Merry Christmas Sheff's Station :)
MSTX- Fda gives thumbs up!! Mobile so can't post the link.
MSTX- MST-188 Significantly Decreased Thrombin Generation in Blood of Sickle Cell Anemia Patients
SAN DIEGO, Nov. 17, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (nyse mkt:MSTX), a clinical-stage biopharmaceutical company, today announced that it will be presenting data from an ex vivo study of MST-188 (vepoloxamer), its lead product candidate, at the 56th Annual Meeting of the American Society of Hematology (ASH) taking place December 6 – 9, 2014 in San Francisco, California.
MSTX- MST-188 Significantly Decreased Thrombin Generation in Blood of Sickle Cell Anemia Patients
SAN DIEGO, Nov. 17, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (nyse mkt:MSTX), a clinical-stage biopharmaceutical company, today announced that it will be presenting data from an ex vivo study of MST-188 (vepoloxamer), its lead product candidate, at the 56th Annual Meeting of the American Society of Hematology (ASH) taking place December 6 – 9, 2014 in San Francisco, California.
SEC cracking down big time this year. Good :)
THLD moving pre market. Looking good.
Nice to see I'm not the only one who feels that way.
No problem sheff and hope all is well.
That made me laugh for some reason :)
It's a blood bath out there:( I need some green! !
If Big Mike did sell this stock to his neighbors like he said, I bet he hasn't stepped outside in a week :) Poor guy is gonna have to move!
Sheff you've been super hot !! Thanks for all the time you put into your board.
It's an otc so it looks like garbage. Sheff's board is for BB stocks. Thanks
TGTX- Roth Capital affirms its Buy/Focus Pick rating and $25 price target on TG Therapeutics (Nasdaq: TGTX) following news that the company exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S.A.
Analyst Joseph Pantginis commented, Given the positive clinical readouts to date with TGR-1202 alone and in combination with TG-1101, we believe acquiring the full rights for TGR-1202 is a favorable course of action. We believe that this way, TGTX would have significant leverage if it chose to pursue a partnership. This is particularly emphasized by the recent favorable terms that Infinity (INFI-NC) secured in the deal with AbbVie (NYSE: ABBV) for its PI3K inhibitor. Recall that the TGR-1202 single agent study showed that 100% of CLL patients treated with # 800mg TGR-1202 exhibited significant nodal reductions and 80% achieving PR or nodal PR. Importantly, TGR-1202 was shown to be safe and well tolerated in patients treated over a year with no hepatotoxicity. The combination study of TG-1101 and TGR-1202 achieved 100% ORR. These data indicate that TGR-1202 is a potential best-in-class PI3K-delta inhibitor as well as very good combinable potential with other drugs and therefore can have potential interest from a partnering standpoint.
It amazes me that a company comes out with great news and it can't seem to hold their gains. Almost better to not give investors the news they wait for.